AI in Healthcare

Today's Stories

1. 1

   Neko Health opens Manhattan clinic with $499 AI exam

   Neko Health, founded by Daniel Ek and CEO Hjalmar Nilsonne, opened its first U.S. clinic in Manhattan yesterday, offering a $499 exam that maps skin, body composition, heart, blood, and metabolic health. At $499, the exam is positioned as a cheaper, faster alternative to traditional preventive care. Nilsonne says the goal is to democratize high-quality preventive health care for millions or hundreds of millions of people.

   The promise of preventive AI health care hinges on whether these clinics can scale beyond a single Manhattan location. Watch how many more U.S. clinics Neko Health opens next.

2. 2

   Basecamp Research raises $140m to scale AI therapy push

   Basecamp Research raised $140m in an oversubscribed Series C led by S32, with backing from Nvidia, The Rockefeller Foundation, and others, to train new EDEN models and advance AI-designed therapies. The funding is expected to expand Basecamp's pharmaceutical partnerships and move its AI-designed in vivo cell therapies closer to clinical development.

   The approach pairs EDEN's DNA design with large serine recombinases, and its success hinges on whether this can sidestep the complexity and high manufacturing costs of current cell therapies.

3. 3

   Enveda Biosciences raises $311 million in Series E

   Enveda Biosciences raised $311 million in a Series E led by Catalio Capital Management, with 16 other backers including Surveyor Capital, T. Rowe Price and Lux Capital. The sum rivals totals secured in some of biotech's larger IPOs this year, and notably comes from private investors rather than the public markets.

   Value hinges on whether Enveda's partnered drug candidates deliver clinical validation; its ENV-294 eczema and asthma Phase 2 trials are underway.

4. 4

   Basecamp Research raises $140M for AI-designed cell therapies

   Basecamp Research announced $140 million in Series C funding led by S32, a fund affiliated with Google co-founder Bill Maris, joined by NATO, Nvidia and the Anthology Fund, a joint venture between Anthropic and Menlo Ventures. The company's initial focus is using AI-designed therapies to modify patient cells to cure disease, and CEO Glen Gowers says the future of medicine lies in reprogramming the body to repair itself.

   The capital will accelerate drug development and seal more partnerships with pharmaceutical companies, but it remains to be seen how quickly AI-designed medicines can reach the market.

5. 5

   Enveda raises $311M at $2B for nature-derived AI drugs

   Enveda raised $311M in a round that valued the AI biotech at $2 billion. It is currently testing nature-derived drugs for skin conditions and for preserving weight loss after stopping GLP-1s. The $2 billion valuation signals investor backing for Enveda's approach of turning nature-derived compounds into clinical-stage treatments. The drugs now in testing target skin conditions and weight-loss maintenance after GLP-1s.

   The outcome hinges on whether those clinical trials advance, since the drugs are still in testing. Watch for trial results on the skin and weight-loss programs.

6. 6

   OpenAI launches MentalHealthBench, 80+ experts, 22 countries

   OpenAI introduced MentalHealthBench, an open benchmark co-created with more than 80 licensed mental health experts from 22 countries, built from synthetic conversations and graded by GPT‑5.6 Sol. OpenAI says the results show steady improvement in how AI systems help with mental health situations, giving researchers a shared, expert-informed way to measure safety and usefulness.

   The benchmark is not a substitute for professional care, and OpenAI says no benchmark captures everything in a personal conversation, so scores may not reflect real-world safeguards.